These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27393627)

  • 1. Irreversible electroporation enhances delivery of gemcitabine to pancreatic adenocarcinoma.
    Bhutiani N; Agle S; Li Y; Li S; Martin RC
    J Surg Oncol; 2016 Aug; 114(2):181-6. PubMed ID: 27393627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma.
    Bhutiani N; Li Y; Zheng Q; Pandit H; Shi X; Chen Y; Yu Y; Pulliam ZR; Tan M; Martin RCG
    Ann Surg Oncol; 2020 Oct; 27(11):4348-4359. PubMed ID: 32681477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma.
    Huang KW; Yang PC; Pua U; Kim MD; Li SP; Qiu YD; Song TQ; Liang PC
    J Surg Oncol; 2018 Jul; 118(1):31-36. PubMed ID: 29878378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic Adenocarcinoma Treated With Irreversible Electroporation Case Report: First Experience and Outcome.
    Trueba-Arguiñarena FJ; de Prado-Otero DS; Poves-Alvarez R
    Medicine (Baltimore); 2015 Jul; 94(26):e946. PubMed ID: 26131840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer - A multi-institutional clinical study in Asia.
    Yang PC; Huang KW; Pua U; Kim MD; Li SP; Li XY; Liang PC
    Eur J Surg Oncol; 2020 May; 46(5):811-817. PubMed ID: 31839436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: Our preliminary experience.
    Belfiore MP; Ronza FM; Romano F; Ianniello GP; De Lucia G; Gallo C; Marsicano C; Di Gennaro TL; Belfiore G
    Int J Surg; 2015 Sep; 21 Suppl 1():S34-9. PubMed ID: 26118600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of calcium electroporation, electrochemotherapy, and irreversible electroporation on quality of life and progression-free survival in patients with pancreatic cancer: IREC clinical study.
    Rudno-Rudzińska J; Kielan W; Guziński M; Kulbacka J
    Adv Clin Exp Med; 2021 Jul; 30(7):765-770. PubMed ID: 34313408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New therapeutic strategy: Personalization of pancreatic cancer treatment-irreversible electroporation (IRE), electrochemotherapy (ECT) and calcium electroporation (CaEP) - A pilot preclinical study.
    Rudno-Rudzińska J; Kielan W; Guziński M; Płochocki M; Antończyk A; Kulbacka J
    Surg Oncol; 2021 Sep; 38():101634. PubMed ID: 34303953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study.
    Vogel JA; Rombouts SJ; de Rooij T; van Delden OM; Dijkgraaf MG; van Gulik TM; van Hooft JE; van Laarhoven HW; Martin RC; Schoorlemmer A; Wilmink JW; van Lienden KP; Busch OR; Besselink MG
    Ann Surg Oncol; 2017 Sep; 24(9):2734-2743. PubMed ID: 28560601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irreversible electroporation in locally advanced pancreatic cancer: A call for standardization of energy delivery.
    Martin RC; Durham AN; Besselink MG; Iannitti D; Weiss MJ; Wolfgang CL; Huang KW
    J Surg Oncol; 2016 Dec; 114(7):865-871. PubMed ID: 27546233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
    Zagon IS; Jaglowski JR; Verderame MF; Smith JP; Leure-Dupree AE; McLaughlin PJ
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):510-20. PubMed ID: 15947928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
    Damaraju VL; Bouffard DY; Wong CK; Clarke ML; Mackey JR; Leblond L; Cass CE; Grey M; Gourdeau H
    BMC Cancer; 2007 Jul; 7():121. PubMed ID: 17608948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study.
    Ruarus AH; Vroomen LGPH; Geboers B; van Veldhuisen E; Puijk RS; Nieuwenhuizen S; Besselink MG; Zonderhuis BM; Kazemier G; de Gruijl TD; van Lienden KP; de Vries JJJ; Scheffer HJ; Meijerink MR
    Radiology; 2020 Jan; 294(1):212-220. PubMed ID: 31687922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent chemotherapy alone versus irreversible electroporation followed by chemotherapy on survival in patients with locally advanced pancreatic cancer.
    Belfiore G; Belfiore MP; Reginelli A; Capasso R; Romano F; Ianniello GP; Cappabianca S; Brunese L
    Med Oncol; 2017 Mar; 34(3):38. PubMed ID: 28161827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of safety for electrochemotherapy and irreversible electroporation ablation therapies in patients with cardiac pacemakers.
    Jarm T; Krmac T; Magjarevic R; Kos B; Cindric H; Miklavcic D
    Biomed Eng Online; 2020 Nov; 19(1):85. PubMed ID: 33198769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Maggino L; Malleo G; Marchegiani G; Viviani E; Nessi C; Ciprani D; Esposito A; Landoni L; Casetti L; Tuveri M; Paiella S; Casciani F; Sereni E; Binco A; Bonamini D; Secchettin E; Auriemma A; Merz V; Simionato F; Zecchetto C; D'Onofrio M; Melisi D; Bassi C; Salvia R
    JAMA Surg; 2019 Oct; 154(10):932-942. PubMed ID: 31339530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
    Kwon D; McFarland K; Velanovich V; Martin RC
    Surgery; 2014 Oct; 156(4):910-20. PubMed ID: 25239345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
    An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
    Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies.
    Mohammad RM; Al-Katib A; Pettit GR; Vaitkevicius VK; Joshi U; Adsay V; Majumdar AP; Sarkar FH
    Clin Cancer Res; 1998 Apr; 4(4):887-94. PubMed ID: 9563882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
    Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
    Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.